Astragalus Polysaccharides (APS), an active metabolite of Astragalus membranaceus Bunge has been shown to be effective in attenuating metabolic disorders induced by HFD, including decreasing the extent of hepatic steatosis, inhibiting body mass gain, and improving insulin resistance (Liu et al., 2020). This evidence concerns the gene INS and fatty liver disease.